6.0 References #
1. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bower TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346:561-564.
2. Di Marzo V, Petrocellis LD. The endogenous cannabinoid signalling system: chemistry, biochemistry and physiology. Internet Journal of Science, Biological Chem 1. 1997;WWW:
http://www.netsci-journal.com.
3. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther. 1997;74(2):129-180.
4. Miller LL, Branconnier RJ. Cannabis - Effects on memory and the cholinergic limbic system. Psych Bull. 1984;93:441-456.
5. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, De Costa BR, Rice KC. Cannabinoid receptor localization in the brain. Proc Natl Acad Sci USA. 1990;87:1932-1936.
6. Munro S, Thomas KL, Ab-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61-65.
7. Devane WA. New dawn of cannabinoid pharmacology. TiPs. 1994;15:40-41.
8. Lynn AB, Herkenham M. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol Exp Ther. 1994;268:1612-23.
9. Schatz AR, Lee M, Condie RB, Pulaski JT, Kaminski NE. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol Appl Pharmacol. 1997;142 (2):278-287.
10. Bayewitch M, Rhee RH, Avidor-Reiss T, Brewer A, Mechoulam R, Vogel. (-)-Delta-(9)-Tetrahydro-cannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J Biol Chem. 1996;271:9902-9905.
11. Felder CC, Veluz JS, Williams HC, Briley EM, Matsuda LA. Cannabinoid agonists stimulate both receptor and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. Mol Pharmacol. 1992;42:838-845.
12. Shire D, Carillon C, Kaghad M, Calandra B, Rinaldi-Carmona M, Le Fur G, Caput D, Ferrari P. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J Biol Chem. 1995;270:3726-3731.
13. Rinaldi-Carmona M, Calandra B, Shire D, Bouaboula M, Oustric D, Barth F, Casellas P, Ferrara P, Le Fur G. Characterization of two cloned human CB1 cannabinoid receptor isoforms. J Pharmacol Exp Ther. 1996;278(2):871-878.
14. Devane WA, Manus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946-1949.
15. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther. 1994;270:219-227.
16. Romero J, Garcia L, Fernandez-Ruiz JJ, Cebeira M, Ramos JA. Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to delta 9-tetrahydrocannabinol. Pharmacol Biochem Behav. 1995;51:731-737.
17. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AK, Gopher A, Almog S, Martin BR, Compton DR, Pertwee RG, Griffin G, Bayewitch M, Barg J, Vogel Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 1995;50:83-90.
18. Lee M, Yang KH, Kaminski NE. Effects of putative cannabinoid receptor ligands, anandamide and 2-arachidonoyl-glycerol on immune function in B6C3F1 mouse splenocytes. J Pharmacol Exp Ther. 1995;275:529-536.
19. Sugiura T, Kondo S, Sukagara A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku K. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun. 1995;215:89-97.
20. Shohami E, Weidenfeld J, Ovadia H, Vogel Z, Hanus L, Fride E, Breuer A, Ben-Shabat S, Shaskin T, Mechoulam R. Endogenous and synthetic cannabinoids: recent advances. CNS Drug Rev. 1997;4:429-451.
21. Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA. 1995;92:3376-3380.
22. Hanus L, Gopher A, Almog S, Mechoulam R. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem. 1993;36:3032-3034.
23. Rinaldi-Carmoni M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maurani J, Neliat G, Caput D, Ferrara P, Soubrie P, Breliere JC, Le Fur G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBBS Lett. 1994;350:240-244.
24. Barg J, Fride E, Hanus L, Levy R, Matus-Leibovitch N, Heldman E, Bayewitch M, Mechoulam R, Vogel Z. Cannabinomimetic behavioural effects of and adenylate cyclase inhibition by two new endogenous anandamides.. Eur Journal Pharmacol. 1995;287:145-152.
25. Cravatt BF, Prospero-Garcia O, Siuzdak G, Gilula NB, Henriksen SJ, Boger DL, Lerner RA. Chemical characterization of a family of brain-lipids that induce sleep. Science. 1995;268:1506-1509.
26. Sheskim T, Hanus L, Slager J, Vogel Z, Mechoulam R. Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J Med Chem. 1997;40:659-667.
27. Maurelli S, Bisogno T, De Petrocelli L, Di Luccia A, Marino G, Di Marzo V. Two novel classes of neuroactive fatty acid amides are substrates for mouse neuroblastoma anandamide amidohydrolase. FEBS Lett. 1995;377:82-86.
28. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature. 1994;372:686-691.
29. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA. 1990;87:1932-1936.
30. Shen M, Piser TM, Seybold VS, Thayer SA. Cannabinoid receptor agonists inhibit glutamateric synaptic transmission in rat hippocampal cultures. J Neurosci. 1996;16:4322-4334.
31. Chan PKY, Chan SCY, Yung WH. Presynaptic inhibition of GABAergic inputs to rat substantia nigra pars reticulata neurones by a cannabinoid agonist. NeuroReport. 1998;9:671-675.
32. Hoffman AF, Lupica CR. Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus. J Neurosci. 2000;20:2470-2479.
33. Takahishi KA, Linden DJ. Cannabinoid receptor modulation of synapses received by cerebellar purkinje cells. J Neurophysiol. 2000;83:1167-1180.
34. Heyser CJ, Hampson RE, Deadwyler SA. Effects of delta-9-tetrahydrocannabinol on delayed match to sample performance in rats: alterations in short-term memory associated with changes in task specific firing in hippocampal cells. J Pharmacol Exp Ther. 1993;264:294-307.
35. Lichtman AH, Dimen KR, Martin BR. Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacology (Berl). 1995;119:282-290.
36. Hampson RE, Deadwyler SA. Cannabinoids, hippocampal function and memory. Life Sci. 1999;65:715-723.
37. Kim DJ, Thayer SA. Activation of CB1 cannabinoid receptors inhibits neurotransmitter release from identified synaptic sites in rat hippocampal cultures. Brain Res. 2000;852:398-405.
38. Katona I, Sperlagh B, Sik A, Kafalvi A, Vizi ES, Mackie K, Freund TF. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurones. J Neurosci. 1999;19:4544-4558.
39. Irving AJ, Coutts AA, Harvey J, Rae MG, Mackie K, Bewick GS, Pertwee RG. Functional expression of cell surface cannabinoid CB1 receptors on presynaptic inhibitory terminals in cultured rat hippocampal neurons. Neurosci. 2000;98:253-262.
40. Friedman HV, Bresler T, Garner CC, Ziv NE. Assembly of new individual excitatory synapses: time course and temporal order of synaptic molecule recruitment. Neuron. 2000;27:57-69.
41. Pertwee RG. Cannabinoid receptors and pain. Prog Neurobiol. 2001;63:569-611.
42. Marsiconi G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgänsberger, Di Marzo V, Lutz B. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 2002;418:530-534.
43. Falls WA, Miserendino MJ, Davis M. Extinction of fear-potentiated startle: blockade by infusion of an NMDA antagonist into the amygdala. J Neurosci. 1992;12:854-863.
44. Schlicker E, Timm J, Gother M. Cannabinoid receptor-mediated inhibition of dopamine release in the retina. Naunyn Schmiedeberg's Arch Pharmacol. 1996;354:791-795.
45. Ishac EJN, Jiang L, Lake KD, Varga K, Abood ME, Kunos G. Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol. 1996;118:2023-2028.
46. Wickens AP, Pertwee RG. Δ9-Tetrahydrocannabinol and anandamide enhance the ability of muscimol to induce catalepsy in the globus pallidus of rats. Eur J Pharmacol. 1993;250:205-208.
47. Romero J, Garcia-Palomero E, Fernandez-Ruiz JJ, Ramos JA. Involvement of GABA(B) receptors in the motor inhibition produced by agonists of brain cannabinoid receptors. Behav Pharmacol. 1996;7:299-302.
48. Zygmunt PM, Petersson J, Andersson DA, Chuang H-H, Sorgard M, Di Marzo V, Julius D, Hogestatt ED. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 1999;400:452-457.
49. Ledent C, Valverde O, Cossu G, Petitet F, Aubert J-F, Beslot F, Böhme G, Imperato A, Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M. Unresponsiveness to Cannabinoids and Reduced Addictive Effects of Opiates in CB1 Receptor Knockout Mice. Science. 1999;283:401-404.
50. Straiker A, Stella N, Piomelli D, Mackie K, Karten HJ, Maguire G. Cannabinoid CB1 receptors and ligands in vertebrate retina: localization and function of an endogenous signaling system. PNAS. 1999;96:14565-14570.
51. Schmid PC, Krebsbach RJ, Perry SR, Dettmer TM, Maasen JL, Schmid HHO. Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamides in mammalian brain. FEBS Lett. 1995;375:117-120.
52. Kempe K, Hsu FF, Bohrer A, Turk J. Isotope dilution mass spectrometric measurements indicate that arachidonylethanolamide, the proposed endogenous ligand of the cannabinoid receptor, accumulates in rat brain tissue post mortem but is contained at low levels in or absent from fresh tissue. J Biol Chem. 1996;271:17287-17295.
53. Felder CC, Nielsen A, Briley EM, Palkovitis M, Priller J, Axelrod J, Nguyen DN, Richardson JM, Riggin RM, Koppel GA, Paul SM, Becker GW. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett. 1996;393:231-235.
54. Schmid HHO, Schmid PC, Natarajan V. N-Acylated glycerophospholipids and their derivatives. Prog Lipid Res. 1990;29:1-43.
55. Schmid PC, Reddy PV, Natarajan V, Schmid HHO. Metabolism of N-acylethanolamine phospholipids by a mammalian phosphodiesterase of the phospholipase D type. J Biol Chem. 1983;258:9302-9306.
56. Weidenfeld J, Feldman S, Mechoulam R. Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat. Neuroendocrinology. 1994;59:110-112.
57. Wenger T, Toth BE, Martin BR. Effects of anandamide (endogen cannabinoid) on anterior pituitary hormone secretion in adult ovariectomized rats. Life Sci. 1995;56:2057-2063.
58. Giannikou P, Yiannakakis N, Frangkakis G, Probonas K, Wenger T. Anandamide (endogen cannabinoid) decreases serum prolactin level in pregnant rat. Neuroendocinol Lett. 1995;17:281-287.
59. Bisogno T, Maurelli S, Melck D, De Petrocellis L, Di Marzo V. Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J Biol Chem. 1997;272:3315-3323.
60. Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA. 1995;92:3376-3380.
61. Schwarz H, Blanco FJ, Lotz M. Anandamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis. J Neuroimmunol. 1994;55:107-115.
62. Mazzari S, Canella R, Petrelli L, Marcolongo G, Leon A. N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur J Pharmacol. 1996;300:227-236.
63. Gérard CM, Mollereau C, Vassart G, Parmentier M. Nucleotide sequence of a human cannabinoid receptor cDNA. Nucleic Acids Res. 1990;18:7142-134.
64. Sugiura T, Kondo S, Sukagawa A, Tonegawa T, Nakane S, Yamashita A, Waku K. Enzymatic synthesis of anandamide, an endogenous cannabinoid receptor ligand, through N-acylphosphatidylethanolamine pathway in testis: involvement of Ca2+-dependent transacylase and phosphodiesterase activities. Biochem Biophys Res Comm. 1996;218:113-117.
65. Pertwee RG, Joeadigwe G, Hawksworth GM. Further evidence for the presence of cannabinoid CB1 receptors in mouse vas deferens. Eur J Pharmacol. 1996;296:169-172.
66. Chang MC, Berkery D, Schuel R, Laychock SG, Zimmerman AM, Zimmerman S, Schuel H. Evidence for a cannabinoid receptor in sea urchin sperm and its role in blockade of the acrosome reaction. Mol Reprod Develop. 1993;36:507-516.
67. Schuel H, Berkery D, Schuel R, Chang MC, Zimmerman AM, Zimmerman S. Reduction of the fertilizing capacity of sea urchin sperm by cannabinoids derived from marihuana: Inhibition of the acrosome reaction induced by egg jelly. Mol Reprod Develop. 1991;29:51-59.
68. Schuel H, Goldstein E, Mechoulam R, Zimmerman AM, Zimmerman S. Anandamide (arachidoynlethanolamide), a brain cannabinoid receptor agonist, reduces sperm fertilizing capacity in sea urchins by inhibiting the acrosome reaction. Proc Natl Acad Sci USA. 1994;91:7678-7682.
69. Bisogno T, Ventriglia M, Mosca M, Milone A, Cimino G, Di Marzo V. Occurrence and metabolism of anandamide and related acylethanolamides in ovaries of the sea urchin Paracentrotus lividus. Biochim Biophys Acta. 1997;1345:338-348.
70. Paria BC, Das SK, Dey SK. The preimplantation mouse embryo is a target for cannabinoid ligand-receptor signalling. Proc Natl Acad Sci USA. 1995;92:9460-9464.
71. Paria BC, Deutsch DD, Dey SK. The uterus is a potential site for anandamide synthesis and hydrolysis: differential profiles of anandamide synthase and hydrolase activities in the mouse uterus during the periimplantation period. Mol Repr Develop. 1996;45:183-192.
72. Grinspoon, L, Bakalar, JB. Marihuana as medicine: a plea for consideration. J Am Med Assoc. 1995;273:1875-1876.
73. Voth E, Schwartz R. Medicinal applications of delta-9-tetrahydrocannabinol and marijuana. Ann Intern Med. 1997;126:791-798.
74. De Petrocellis L Melck D, Palmisano A, Bisogno T, Laezza C, Bifulco M, Di Marzo V. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci USA. 1998;95:8375-8380.
75. Sánchez C, Galve-Roperh I, Canova C, Brachet P, Guzmán M. 9-Tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett. 1998;436:6-10.
76. Galve-Roperh I, Sánchez C, Cortés ML, Gomez del Pulgar T, Izquierdo M, Guzmán M. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-related kinase activation. Nature. 2000;6:313-319.
77. Skaper SD, Buriani A, Dal Toso R, Petrelli L, Romanello S, Facci L, Leon A. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci USA. 1996;93:3984-3989.
78. Shen M, Thayer SA. Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol Pharmacol. 1998;54:459-462.
79. Nagayama T, Sinor AD, Simon RP, Chen J, Graham SH, Jin K, Greenberg DA. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci. 1999;19:2987-2995.
Bookmarks